Radiotherapy and immunogenic cell death

DOI: 10.1016/j.semradonc.2014.07.005
Seminars in Radiation Oncology, 2015, 25, 11-7.

#	Paper	IF	Citations
311	Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. **2017**, 6, 113-118		11
310	Combinatorial strategies for the induction of immunogenic cell death. **2015**, 6, 187		228
309	Modulation of inflammation by low and high doses of ionizing radiation: Implications for benign and malign diseases. **2015**, 368, 230-7		83
308	Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. **2015**, 16, 795-803		409
307	The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where. **2015**, 154, 36-56		104
306	Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. **2015**, 21, 4073-4085		70
305	Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives. **2015**, 41, 844-52		81
304	Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation. **2016**, 6, 141		88
303	Targeted Radionuclide Therapy of Human Tumors. **2015**, 17,		82
302	Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?. **2016**, 12, 54-65		2
301	The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer. **2016**, 1, 8		6
300	Policy Implications of Proton Radiation Therapy: Toward an Evidence-Based Approach for Implementing Novel Oncologic Technologies. **2016**, 95, 560-561		1
299	Carbon-Ion Therapy: One More Step in the Endless Quest for the Ideal Dose Distribution. **2016**, 95, 561		3
298	Emerging Opportunities and Challenges in Cancer Immunotherapy. **2016**, 22, 1845-55		172
297	Radiotherapy: Changing the Game in Immunotherapy. **2016**, 2, 286-294		200
296	Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology. **2016**,		
295	Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy. **2016**,		3

294	Immunogenic Apoptotic Cell Death and Anticancer Immunity. **2016**, 930, 133-49	60
293	Radiobiology of Glioblastoma. **2016**,	2
292	The Immune System and Its Contribution to the Radiotherapeutic Response of Glioblastoma. **2016**, 155-175	
291	The immune mechanisms of abscopal effect in radiation therapy. **2016**, 40, 10-24	94
290	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. **2016**, 5, e1149674	41
289	Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation. **2017**, 77, 1310-1321	29
288	Calcium, oxidative stress and connexin channels, a harmonious orchestra directing the response to radiotherapy treatment?. **2017**, 1864, 1099-1120	31
287	Synergistic effect of Ebselen and gamma radiation on breast cancer cells. **2017**, 93, 784-792	15
286	The melatonin immunomodulatory actions in radiotherapy. **2017**, 9, 139-148	55
285	Cancer immunotherapy: how low-level ionizing radiation can play a key role. **2017**, 66, 819-832	37
284	Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. **2017**, 18, 36-42	92
283	N-dihydrogalactochitosan as a potent immune activator for dendritic cells. **2017**, 105, 963-972	14
282	Improved infield response rates and overall survival in patients with metastatic melanoma receiving higher biological equivalent doses of radiation with ipilimumab. **2017**, 6, 215-223	1
281	Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. **2017**, 66, 247-258	122
280	Mathematical model of tumor volume dynamics in mice treated with electrochemotherapy. **2017**, 55, 1085-1096	1
279	Combining Radiotherapy and Immunotherapy: Emerging Preclinical Observations of Lymphocyte Costimulatory and Inhibitory Receptor Modulation. **2017**, 151-169	
278	Increasing the Therapeutic Ratio of Radiotherapy. **2017**,	1
277	The role of immunonutritional support in cancer treatment: Current´evidence. **2017**, 36, 1457-1464	40

276	Developing T-cell therapies for lymphoma without receptor engineering. **2017**, 2017, 622-631	2
275	Developing T-cell therapies for lymphoma without receptor engineering. **2017**, 1, 2579-2590	4
274	The Immunoregulatory Potential of Particle Radiation in Cancer Therapy. **2017**, 8, 99	39
273	Controversy and perspective in the management of marginally operable stage IIIA non-small cell lung cancer: response to Editorial by Charlotte Billiet and Dirk De Ruysscher and Editorial by Dr. Wanpu Yan and Dr. David R. Jones. **2017**, 9, E881-E883	
272	The Abscopal Effect in the Era of Cancer Immunotherapy: a Spontaneous Synergism Boosting Anti-tumor Immunity?. **2018**, 13, 113-123	21
271	Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial. **2018**, 30, 201-203	5
270	Mechanisms of inflammatory responses to radiation and normal tissues toxicity: clinical implications. **2018**, 94, 335-356	78
269	Treatment of Canine Oral Melanoma with Nanotechnology-Based Immunotherapy and Radiation. **2018**, 15, 3717-3722	53
268	The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy. **2018**, 91, 20170762	37
267	Out of the darkness and into the light: New strategies for improving treatments for locally advanced non-small cell lung cancer. **2018**, 421, 59-62	5
266	Prognostic significance of HPV status in the re-irradiation of recurrent and second primary cancers of the head and neck. **2018**, 39, 257-260	3
265	Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based Study. **2018**, 18, 125-135.e3	3
264	Abscopal effect of radiation on bone metastases of breast cancer: A case report. **2018**, 19, 20-24	16
263	Immunogenic Stress and Death of Cancer Cells in Natural and Therapy-Induced Immunosurveillance. **2018**, 215-229	2
262	Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model. **2018**, 6, 17	43
261	Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. **2018**, 118, 1322-1328	15
260	Radiation Therapy Combined with Cowpea Mosaic Virus Nanoparticle in Situ Vaccination Initiates Immune-Mediated Tumor Regression. **2018**, 3, 3702-3707	39
259	Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?. **2018**, 19, 1-11	34

258	Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!. **2018**, 32, 203-224	14
257	Overcoming Immune Suppression in the Tumor Microenvironment: Implications for Multi-modal Therapy. **2018**, 13-38	
256	HOCl and the control of oncogenesis. **2018**, 179, 10-23	27
255	Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers. **2018**, 9, 225-230	1
254	Radiation therapy and immunotherapy-a potential combination in cancer treatment. **2018**, 25, e454-e460	18
253	Radiotherapy and immune response: the systemic effects of a local treatment. **2018**, 73, e557s	76
252	Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer. **2018**, 9, 3018	68
251	Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?. **2018**, 6,	5
250	Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment. **2018**, 10,	25
249	The Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Head and Neck Cancer Patients Treated with Radiotherapy. **2018**, 7,	23
248	The DNA damage response in immunotherapy and radiation. **2018**, 3, 527-533	18
247	Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. **2018**, 7, e1496881	18
246	Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell-mediated remissions. **2018**, 2, 2568-2580	5
245	Targeted alpha therapy using Radium-223: From physics to biological effects. **2018**, 68, 47-54	14
244	Combining ADCs with Immuno-Oncology Agents. **2018**, 11-44	4
243	Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: Study. A more efficient combination. **2018**, 9, 1973-1977	1
242	PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models. **2018**, 144, 1909-1920	8
241	Principles and Developments in Cancer Immunotherapy and Approaches for Combination with Tumour Irradiation. **2018**, 1-10	

240	Cancer Immunology. **2018**, 409-419	
239	Towards a personalized iPSC-based vaccine. **2018**, 2, 277-278	2
238	Radiation-Induced Transformation of Immunoregulatory Networks in the Tumor Stroma. **2018**, 9, 1679	19
237	Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs. **2018**, 6, 910-920	145
236	Characterization of the adenosinergic system in a zebrafish embryo radiotherapy model. **2019**, 224, 108572	0
235	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. **2019**, 32, 1772-1785	33
234	Construction of Nucleus-Targeting Iridium Nanocrystals for Photonic Hyperthermia-Synergized Cancer Radiotherapy. **2019**, 15, e1903254	16
233	Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting. **2019**, 9, 1009	49
232	Cancer of the oesophagus and lymph nodes management in the neoadjuvant or definitive radiochemotherapy setting. **2019**, 23, 682-687	2
231	Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. **2019**, 105, 1065-1073	41
230	Cold Tumors: A Therapeutic Challenge for Immunotherapy. **2019**, 10, 168	338
229	Intrinsic cancer vaccination. **2019**, 151-152, 2-22	18
228	Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. **2019**, 7, 160	73
227	Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC). **2019**, 94, 93-100	6
226	Selenium as an adjuvant for modification of radiation response. **2019**, 120, 18559-18571	11
225	Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review. **2019**, 228, 228-241	62
224	Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab. **2019**, 11, e4083	12
223	Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models. **2019**, 7, 64	15

222	The immune mediated role of extracellular HMGB1 in a heterotopic model of bladder cancer radioresistance. **2019**, 9, 6348	12
221	Turning "Cold" Into "Hot" Tumors-Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers. **2019**, 9, 163	55
220	Evolution of the Supermodel: Progress in Modelling Radiotherapy Response in Mice. **2019**, 31, 272-282	9
219	Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization. **2019**, 14, 41-53	39
218	Polyphenols: Immunomodulatory and Therapeutic Implication in Colorectal Cancer. **2019**, 10, 729	56
217	Role of the tumor microenvironment in pancreatic cancer. **2019**, 3, 130-137	53
216	Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors. **2019**, 10, 407	32
215	Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. **2019**, 10, 899	104
214	Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses. **2019**, 25, 7576-7584	24
213	mTOR-Mediated Antioxidant Activation in Solid Tumor Radioresistance. **2019**, 2019, 5956867	16
212	CD47-SIRP Signaling Induces Epithelial-Mesenchymal Transition and Cancer Stemness and Links to a Poor Prognosis in Patients with Oral Squamous Cell Carcinoma. **2019**, 8,	29
211	Prostate radiotherapy in newly diagnosed metastatic prostate cancer. **2019**, 29, 620-628	2
210	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. **2019**, 11,	19
209	Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery. **2019**, 3, 1-16	13
208	Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?. **2018**, 9, 3107	48
207	High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles. **2019**, 5, 122-144	18
206	CD47 agonist peptide PKHB1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells. **2019**, 110, 256-268	28
205	An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models. **2019**, 103, 697-708	35

204	Metal Drugs and the Anticancer Immune Response. **2019**, 119, 1519-1624	146
203	Tumor inherent interferons: Impact on immune reactivity and immunotherapy. **2019**, 118, 42-47	13
202	Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer. **2020**, 69, 355-364	17
201	Systemic Immunostimulatory Effects of Radiation Therapy Improves the Outcomes of Patients With Advanced NSCLC Receiving Immunotherapy. **2020**, 43, 218-228	5
200	Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?. **2020**, 207, 107450	54
199	Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer. **2020**, 8, 94-107	10
198	Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes. **2019**, 9, 1381	13
197	Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). **2020**, 12,	1
196	Impacts of post-radiotherapy lymphocyte count on progression-free and overall survival in patients with stage III lung cancer. **2020**, 11, 3139-3144	4
195	Enhancing the efficacy of immunotherapy using radiotherapy. **2020**, 9, e1169	16
194	Bip inhibition in glioma stem cells promotes radiation-induced immunogenic cell death. **2020**, 11, 786	2
193	Chitosan/γPGA nanoparticles-based immunotherapy as adjuvant to radiotherapy in breast cancer. **2020**, 257, 120218	27
192	Engineering immunogenic cell death with nanosized drug delivery systems improving cancer immunotherapy. **2020**, 66, 36-43	4
191	The interactions and communications in tumor resistance to radiotherapy: Therapy perspectives. **2020**, 87, 106807	19
190	HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity. **2020**, 13, 6859-6871	10
189	Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers. **2020**, 12,	6
188	Tumor-Specific Antibody, Cetuximab, Enhances the Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma. **2020**, 11, 591139	7
187	Natural killer cells in cancer biology and therapy. **2020**, 19, 120	101

186	Antitumour dendritic cell vaccination in a priming and boosting approach. **2020**, 19, 635-652	51
185	Immunotherapy in cervix cancer. **2020**, 90, 102088	12
184	SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. **2020**, 13, 105	17
183	Clinical development of therapies targeting TGF□current knowledge and future perspectives. **2020**, 31, 1336-1349	73
182	Stereotactic Radiosurgery and Stereotactic Body Radiotherapy in the Management of Oligometastatic Disease. **2020**, 32, 713-727	8
181	Advances in non and minimal-invasive transcutaneous delivery of immunotherapy for cancer treatment. **2020**, 131, 110753	3
180	Modulated Electro-Hyperthermia-Induced Tumor Damage Mechanisms Revealed in Cancer Models. **2020**, 21,	17
179	Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review. **2020**, 11, 2916-2923	2
178	Therapeutic vaccines for aggressive B-cell lymphoma. **2020**, 61, 3038-3051	5
177	Clinically relevant radioresistant rhabdomyosarcoma cell lines: functional, molecular and immune-related characterization. **2020**, 27, 90	8
176	Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors. **2020**, 14, 13343-13366	37
175	Rationale for the Use of Radiation-Activated Mesenchymal Stromal/Stem Cells in Acute Respiratory Distress Syndrome. **2020**, 9,	8
174	and impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response. **2020**, 24, 116-122	6
173	Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations. **2020**, 25, 100265	1
172	Presence of tumor-infiltrating CD8 T cells and macrophages correlates to longer overall survival in patients undergoing isolated hepatic perfusion for uveal melanoma liver metastasis. **2020**, 9, 1854519	4
171	Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer. **2020**, 123, 10-17	9
170	Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi□ ?, AstraZeneca UK Limited). **2020**, 123, 18-27	5
169	Development of a nano-immunomodulator encapsulating R837 and caffeine for combined radio-/immunotherapy against orthotopic breast cancer. **2020**, 30, 697-706	3

168	Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. **2020**, 8, 1095	12
167	Harnessing the potential of multimodal radiotherapy in prostate cancer. **2020**, 17, 321-338	7
166	Dendritic Cell Maturation Defines Immunological Responsiveness of Tumors to Radiation Therapy. **2020**, 204, 3416-3424	23
165	Safety of nivolumab in combination with prior or concurrent radiation therapy in hepatocellular carcinoma. **2020**, 9, 45-52	0
164	Opportunities for Conventional and in Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. **2020**, 12,	13
163	Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the trial protocol. **2020**, 10, e033009	15
162	A review of cancer immunotherapy: from the past, to the present, to the future. **2020**, 27, S87-S97	182
161	Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancer-A Stimulating Partnership. **2020**, 41, 360-368	0
160	Radiotherapy-Activated Hafnium Oxide Nanoparticles Produce Abscopal Effect in a Mouse Colorectal Cancer Model. **2020**, 15, 3843-3850	17
159	Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram. **2020**, 18, 36	26
158	Pure abscopal effect of radiotherapy in a salivary gland carcinoma: Case report, literature review, and a search for new approaches. **2020**, 24, 226-246	5
157	The Determination of Immunomodulation and Its Impact on Survival of Rectal Cancer Patients Depends on the Area Comprising a Tissue Microarray. **2020**, 12,	2
156	Damage-associated molecular patterns in tumor radiotherapy. **2020**, 86, 106761	25
155	Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives. **2019**, 10, 161-170	4
154	The abscopal effect 67 years later: from a side story to center stage. **2020**, 93, 20200042	36
153	Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. **2020**, 20, 135	10
152	Monitoring CD8a T Cell Responses to Radiotherapy and CTLA-4 Blockade Using [Cu]NOTA-CD8a PET Imaging. **2020**, 22, 1021-1030	10
151	Synergistic effect of cisplatin chemotherapy combined with fractionated radiotherapy regimen in HPV-positive and HPV-negative experimental pharyngeal squamous cell carcinoma. **2020**, 10, 1563	5

150	Harnessing Natural Killer Cells Killing Function in Cancer. **2020**, 91-155	
149	CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection. **2020**, 8, 465-478	46
148	Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. **2020**, 28, 794-804	18
147	An autoimmune-based, paraneoplastic neurologic syndrome following checkpoint inhibition and concurrent radiotherapy for merkel cell carcinoma: case report. **2020**, 196, 664-670	1
146	Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. **2020**, 12,	49
145	Immunogenic clearance-mediated cancer vaccination. **2020**, 549-568	1
144	Combining immunotherapy and radiotherapy in head and neck squamous cell cancers: which perspectives?. **2020**, 32, 196-202	2
143	Cellular cytotoxicity is a form of immunogenic cell death. **2020**, 8,	23
142	Spatially fractionated radiotherapy (SFRT) targeting the hypoxic tumor segment for the intentional induction of non-targeted effects: An study to exploit a new treatment paradigm. **2020**, 14, 11-14	1
141	Ionizing radiation modulates the phenotype and function of human CD4+ induced regulatory T cells. **2020**, 21, 18	9
140	Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. **2021**, 110, 35-52	31
139	Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1. **2021**, 110, 492-506	9
138	IDO-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironment. **2021**, 269, 120388	7
137	Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives. **2021**, 157, 103180	29
136	The immuno-oncological implications of insulin. **2021**, 264, 118716	1
135	Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. **2021**, 142, 83-91	15
134	Peptides that immunoactivate the tumor microenvironment. **2021**, 1875, 188486	5
133	Enhancing Immunity with Nanomedicine: Employing Nanoparticles to Harness the Immune System. **2021**, 15, 7-20	9

132	Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma:. **2021**, 34, 101444	1
131	Radiation Response in the Tumour Microenvironment: Predictive Biomarkers and Future Perspectives. **2021**, 11,	2
130	Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress. **2021**, 12, 145	36
129	Carbon ion triggered immunogenic necroptosis of nasopharyngeal carcinoma cells involving necroptotic inhibitor BCL-x. **2021**, 12, 1520-1530	4
128	Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height. **2021**, 13, 117-125	2
127	Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo-immunotherapy. **2021**, 13, 17218-17235	4
126	Prognostic value and peripheral immunologic correlates of early FDG PET response imaging in a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer.	0
125	Copper-Based Nanoscale Coordination Polymers Augmented Tumor Radioimmunotherapy for Immunogenic Cell Death Induction and T-Cell Infiltration. **2021**, 17, e2006231	12
124	Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor. **2021**, 269, 120635	13
123	Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy. **2021**, 12, 635173	6
122	Immune Checkpoint Inhibition as a Strategy in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer. **2021**, 4, 86-104	
121	Biomarkers of Radiotherapy-Induced Immunogenic Cell Death. **2021**, 10,	10
120	Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients. **2021**, 11,	8
119	Immunotherapy for intracranial metastatic melanoma.	78
118	Zoledronic Acid-Gadolinium Coordination Polymer Nanorods for Improved Tumor Radioimmunotherapy by Synergetically Inducing Immunogenic Cell Death and Reprogramming the Immunosuppressive Microenvironment. **2021**, 15, 8450-8465	15
117	Tumor-associated macrophages: Shifting bad prognosis to improved efficacy in cancer therapies?. **2021**, 015-023	1
116	Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. **2021**, 12, 650486	3
115	Intracranial response after extracranial radiation in a patient with rapidly progressing metastatic melanoma. **2021**, 14,	2

114	A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. **2021**, 10, 2766-2778	1
113	Immunological effects of nano-enabled hyperthermia for solid tumors: opportunity and challenge. 1	
112	Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma. **2021**, 22,	2
111	Inmunoterapia en oncologí de las vís aerodigestivas superiores. **2021**, 50, 1-20	
110	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. **2021**, 13,	3
109	PTTG1 knockdown enhances radiation-induced antitumour immunity in lung adenocarcinoma. **2021**, 277, 119594	2
108	Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma. **2021**, 13,	0
107	Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. **2021**, 13,	14
106	Reconciling two opposing effects of radiation therapy: stimulation of cancer cell invasion and activation of anti-cancer immunity. **2021**, 1-13	
105	Advances in technology and applications of nanoimmunotherapy for cancer. **2021**, 9, 63	1
104	Spatially fractionated radiotherapy: tumor response modelling including immunomodulation. **2021**, 66,	1
103	Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities. **2021**, 11, 738626	1
102	'Le Roi est mort, vive le Roi': New Roles of Radiotherapy in the Treatment of Lymphomas in Combination With Immunotherapy. **2021**,	0
101	Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?. **2021**, 22,	
100	Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors. **2021**, 177, 113927	6
99	Nanoparticle-mediated tumor vaccines for personalized therapy: preparing tumor antigens or ?. **2021**, 9, 2352-2366	1
98	Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy. **2021**, 9, 3983-4001	14
97	Engineering nanomedicine for glutathione depletion-augmented cancer therapy. **2021**, 50, 6013-6041	83

96	Molecular and Cellular Functions of CTLA-4. **2020**, 1248, 7-32	35
95	Next Generation of Cancer Immunotherapy: Targeting the Cancer-Immunity Cycle with Nanotechnology. **2020**, 191-253	1
94	Tumor microenvironment, immune response and post-radiotherapy tumor clearance. **2020**, 22, 2196-2205	11
93	The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma. **2020**, 59, 940-943	1
92	Gas plasma irradiation of breast cancers promotes immunogenicity, tumor reduction, and an abscopal effect in vivo. **2020**, 10, 1859731	14
91	Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion. **2021**, 27, 632-644	20
90	Radiation Inhibits Interleukin-12 Production via Inhibition of C-Rel through the Interleukin-6/ Signal Transducer and Activator of Transcription 3 Signaling Pathway in Dendritic Cells. **2016**, 11, e0146463	8
89	Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response. **2016**, 11, e0159515	26
88	The Future of Combining Carbon-Ion Radiotherapy with Immunotherapy: Evidence and Progress in Mouse Models. **2016**, 3, 61-70	29
87	Comparison of the effects of photon, proton and carbon-ion radiation on the ecto-calreticulin exposure in various tumor cell lines. **2019**, 7, 542	26
86	Identifying the Optimal Fractionation Schedules for Improved Response Rates and Survival in Patients with Metastatic Melanoma Treated with Ipilimumab and Radiotherapy. **2020**, 16, 78-85	0
85	Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors. **2020**, 12,	24
84	Abscopal Effect of Radiotherapy in Imatinib-resistant Dermatofibrosarcoma Protuberans. **2019**, 11, e3857	3
83	Nanotechnologies for Photothermal and Immuno Cancer Therapy: Advanced Strategies Using Copper Sulfide Nanoparticles and Bacterium-Mimicking Liposomes for Enhanced Efficacy. **2021**, 191-208	
82	Antitumor Effects of IL-12 in Preclinical Studies. **2016**, 21-41	
81	Treatment of primary and metastatic tumors through cancer immunotherapy and abscopal effect by targeted antigen-capturing nanoparticles with programmed death-1 blockade. **2018**, 28, 69-76	
80	Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes?. **2021**, 10,	2
79	Cancer nanotechnology: current status and perspectives. **2021**, 8, 34	19

78	Synergy of Immunotherapy and Radiosurgery. **2020**, 355-369	
77	Target-Based Radiosensitization Strategies: Concepts and Companion Animal Model Outlook. **2021**, 11, 768692	2
76	Th balance related host genetic background affects the therapeutic effects of combining carbon-ion radiotherapy with dendritic cell immunotherapy. **2021**,	2
75	Combination Therapies with Y90: Immunoradiation. **2020**, 04, 382-388	0
74	Translational Development and Testing of Theranostics in Combination with Immunotherapies. **2022**, 267-280	
73	Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer.. **2022**, 7, 100857	
72	DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy. **2021**, 17, 4657-4663	2
71	Radiotherapy and Radiosensitization in Breast Cancer: Molecular Targets and Clinical Applications. **2021**, 169, 103566	0
70	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.. **2022**, 23,	4
69	Radiotherapy and immunotherapy combination in head and neck cancer: Does current failure qualify as an ending or is it a key to future success?. **2022**, 125, 105717	0
68	Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy.. **2022**,	4
67	Radiotherapy assisted with biomaterials to trigger antitumor immunity. **2022**,	1
66	Bidirectional Crosstalk between Therapeutic Cancer Vaccines and the Tumor Microenvironment: Beyond Tumor Antigens. **2022**,	
65	A paradigm of cancer immunotherapy based on 2-[18F]FDG and anti-PD-L1 mAb combination to enhance the anti-tumor effect.. **2022**,	1
64	Radiation therapy-induced remodeling of the tumor immune microenvironment.. **2022**,	3
63	Management of Regional Lymph Nodes in Head and Neck Melanoma.. **2022**,	
62	Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer.. **2022**, JCO2101991	0
61	Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.. **2022**,	6

60	The Purinergic Landscape of Non-Small Cell Lung Cancer.. **2022**, 14,	0
59	Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune system.. **2022**, 28, 100796	0
58	Table_1.docx. **2020**,	
57	ROS-triggered Nanoinducer based on Dermatan sulfate enhances immunogenic cell death in melanoma.. **2022**,	3
56	Exosomes Participate in the Radiotherapy Resistance of Cancers.. **2022**, 197, 559-565	1
55	Immunogenic Cell Death, DAMPs and Prothymosin as a Putative Anticancer Immune Response Biomarker.. **2022**, 11,	1
54	The intercellular communications mediating radiation-induced bystander effects and their relevance to environmental, occupational, and therapeutic exposures.. **2022**, 1-59	0
53	Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management.. **2022**,	
52	Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy. 1-12	0
51	Radiotherapy-activated NBTXR3 nanoparticles modulate cancer cell immunogenicity and TCR repertoire. **2022**, 22,	2
50	Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. 2201734	16
49	HIF-1 inhibition Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR). **2022**, 14, 3273	2
48	Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer. **2022**, 10, e004784	
47	Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death. **2022**, 41,	2
46	The combination of radiation therapy and complement C3a inhibition potentiate natural killer cell functions against pancreatic cancer.	
45	Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. 13,	
44	Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy. 13,	0
43	Interaction of Radiotherapy and Hyperthermia with the Immune System: a Brief Current Overview. **2022**, 8, 129-138	

42	Lymphocyte-sparing pelvic radiotherapy for prostate cancer: An in-silico study. **2022**, 23, 127-133	
41	Importance of the endometrial immune environment in endometrial cancer and associated therapies. 12,	0
40	PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy. **2022**, 545, 215852	1
39	The Yin and Yang of Unfolded Protein Response in Cancer and Immunogenic Cell Death. **2022**, 11, 2899	0
38	Immunogenic Cell Death Role in Urothelial Cancer Therapy. **2022**, 29, 6700-6713	0
37	Radiation-induced Cell Death and Its Mechanisms. **2022**, 123, 376-386	0
36	The immune subtypes and landscape of sarcomas. **2022**, 23,	0
35	Is anti-PD-1 immunotherapy a means for post-irradiation tumor clearance in head and neck cancer?. **2022**, 39,	0
34	Radioresistance in rhabdomyosarcomas: Much more than a question of dose. 12,	0
33	Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization. **2022**, 10, e005103	1
32	Translational and Clinical Approach to Combining Immunotherapy with Radiotherapy in the Treatment of Head and Neck Cancer. **2022**,	0
31	Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-101) in Patients with Locally Advanced Pancreatic Cancer. **2022**, 14, 5299	0
30	Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours. **2022**, 6, 1148-1166	1
29	Exploiting Radiation Immunostimulatory Effects To Improve Glioblastoma Outcome.	0
28	Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer. **2022**, 14, 4874	1
27	Implications and Emerging Therapeutic Avenues of Inflammatory Response in HPV+ Head and Neck Squamous Cell Carcinoma. **2022**, 14, 5406	1
26	Development of nanotechnology-mediated precision radiotherapy for anti-metastasis and radioprotection.	1
25	Internal mammary lymph nodal response to neoadjuvant chemotherapy on imaging and breast cancer prognosis. **2022**, 104900	0

24	Radiation Type- and Dose-Specific Transcriptional Responses across Healthy and Diseased Mammalian Tissues. **2022**, 11, 2286	1
23	Identification and Validation of Novel Immunogenic Cell Death- and DNA Damage Response-Related Molecular Patterns Correlated with Immune Status and Prognosis in Hepatocellular Carcinoma. **2023**, 27, 101600	0
22	Feasibility of Intratumoral Anti-PD1 as Treatment of Human Basal Cell Carcinoma: An Explorative Study with Adjuvant Ablative Fractional Laser. **2022**, 14, 5815	0
21	Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation. **2022**, 11, 3826	0
20	Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. **2022**, 3, 1498-1512	2
19	Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors. **2023**, 12,	0
18	Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression. 13,	0
17	The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology. **2022**, 11, 3890	0
16	Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. 13,	0
15	Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control. **2023**, 11, e005011	1
14	Immune Checkpoint Therapy: A New Opportunity for Cancer Treatment. **2023**, 1-20	0
13	Challenges and exploration for immunotherapies targeting cold colorectal cancer. 15, 55-68	0
12	Engineering lactate-modulating nanomedicines for cancer therapy.	1
11	Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T-cell-receptor sequencing.	0
10	Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. 13,	0
9	Application of radiomics in lung immuno-oncology.	0
8	Combining in situ vaccination and immunogenic apoptosis to treat cancer. **2023**, 15, 367-381	0
7	TGF-signaling pathway: Therapeutic targeting and potential for anti-cancer immunity. **2023**, 947, 175678	0

6	Impact of radiation therapy on healthy tissues. **2023**, 69-98	0
5	Reduced radiation exposure to circulating blood cells in proton therapy compared with X-ray therapy in locally advanced lung cancer: Computational simulation based on circulating blood cells. 13,	0
4	Biomineralized MnO2 Nanoplatforms Mediated Delivery of Immune Checkpoint Inhibitors with STING Pathway Activation to Potentiate Cancer Radio-Immunotherapy. **2023**, 17, 4495-4506	0
3	Involvement of inflammasomes in tumor microenvironment and tumor therapies. **2023**, 16,	0
2	Effects of Vitamin E Derivative TMG on the Radiation Protector and Tumor Growth during Radiotherapy. **2023**, 48, 1-8	0
1	Implications of the Organ-Specific Immune Environment for Immune Priming Effect of Radiotherapy in Metastatic Setting. **2023**, 13, 689	0